Clinical Trial Update: Venetoclax Combined With Azactidine in the Treatment of ALAL [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial assessing venetoclax combined with azacitidine for acute leukemia of ambiguous lineage is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia of Ambiguous Lineage

Drugs mentioned

• Venclexta (venetoclax) (venetoclax)
• Vidaza (azacitidine) (azacitidine)

Snippet

Sponsor: Sheng-Li Xue, MD | Conditions: Acute Leukemia of Ambiguous Lineage | Phase 2 | Status: RECRUITING